# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Ty  | pe Response   | s)   |  | 1  |            |  |                  |  |   |   |   |   |                                 |             |
|---|---|--|--|--|------------|--|------------------|--|---|---|---|---|---------------------------------|-------------|
| 1. Name and Address of Reporting Person* SIMON NICHOLAS J III                       |   |  |  | 2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL] |            |  |                  |  |   | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director X 10% Owner |   |   |                                 |             |
| (Last) (First) (Middle) C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE, 31ST FLOOR |   |  |  | 3. Date of Earliest Transaction (Month/Day/Year) 08/17/2004                  |            |  |                  |  | ,   | Office  | r (give title belo  | ow)   | Other (specify                  | below)      |
| BOSTON, MA 02199  |   |  |  | 4. If Amendment, Date Original Filed(Month/Day/Year)                         |            |  |                  |  | 6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by One Reporting Person Form filed by More than One Reporting Person |   |   |   |                                 |             |
| (City) (State) (Zip)  |   |  | Table I - Non-Derivative Securities Acqu |  |            |  |                  | ired, Disposed of, or Beneficially Owned |   |   |   |   |                                 |             |
| (Instr. 3) Date   |   | 2. Transaction<br>Date<br>(Month/Day/Year) | A. Deemed<br>Execution Date, if          | (Instr. 8)   |            | on 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |                  |  | 5. Amount of Securities<br>Beneficially Owned Following<br>Reported Transaction(s)  |   |   | Ownership Form:                                 | Beneficial                      |             |
|   |   |  | (Month/Day/Year)                         | Code   | V          | Amount   | (A)<br>or<br>(D) | Price                                    | (Instr. 3 a   | nstr. 3 and 4)  |   | Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4)  | Ownership<br>(Instr. 4)         |             |
| Common Stock  |   | 08/17/2004                                 |  | S  |            | 13,599<br>(1)  | D                | \$<br>22.444                             | 1,809,998   |   | I   | See<br>Footnote                                 |                                 |             |
| Common Stock  |   | 08/18/2004                                 |  | S  |            | 5,400<br>(3)   | D                | \$ 21.8                                  | 1,804,598   |   | I   | See Footnote (4)                                |                                 |             |
| Common Stock  |   |  |  |  |            |  |                  |  | 922   |   | D   |   |                                 |             |
| Reminder:   | Report on a s   | separate line fo                           | or each class of secu                    | rities beneficially or   | wned direc | Per<br>con   | sons wh          | o resp                                   | form are  | not requ  | ction of inf<br>uired to res<br>OMB cont  | spond unle                                      | ess                             | 1474 (9-02) |
|   |   |  |  | Derivative Securit   |            |  |                  |  |   | y Owned   |   |   |                                 |             |
| Security  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date (Month/Day/            | 3A. Deemed<br>Execution Da<br>any        | 4.<br>Transaction<br>Code<br>Year) (Instr. 8)                                | 5.         | and Expiration Date<br>(Month/Day/Year) A<br>U<br>S<br>(I            |                  | 7. Ti<br>Amo<br>Undo<br>Secu             | tle and<br>ount of<br>erlying<br>rities<br>r. 3 and   | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)   | 9. Number<br>Derivative<br>Securities<br>Beneficiall<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4) | Owners Form o Derivat Securit Direct ( or India | Beneficial Ownership (Instr. 4) |             |
|   |   |  |  | Code V   | (A) (D)    | Dat<br>Exc   |                  | Expirat<br>Date                          | tion Title  | Amount<br>or<br>Number<br>of<br>Shares  |   |   |                                 |             |

### **Reporting Owners**

|   | Relationships |              |         |       |  |  |
|---|---------------|--------------|---------|-------|--|--|
| Reporting Owner Name / Address  | Director      | 10%<br>Owner | Officer | Other |  |  |
| SIMON NICHOLAS J III<br>C/O MPM ASSET MANAGEMENT<br>111 HUNTINGTON AVENUE, 31ST FLOOR<br>BOSTON, MA 02199 | X             | X            |         |       |  |  |

#### **Signatures**

| /s/ Nicholas J. Simon, III      | 08/18/2004 |  |  |  |
|---------------------------------|------------|--|--|--|
| **Signature of Reporting Person | Date       |  |  |  |

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The shares were sold as follows: 761 by MPM BioVentures III, L.P. ("BVIII"); 11,320 by MPM BioVentures III-QP, L.P. ("BVIII QP"); 957 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BVIII KG"); 342 by MPM BioVentures III Parallel Fund, L.P. ("BVIII PF"); and 219 MPM Asset Management Investors 2003 BVIII LLC ("BVIII LC"), MPM BioVentures III-QP, L.P. ("BVIII CP") and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP") and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP") and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP") and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP") and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP") and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct and indirect portrops of BVIII DVIII CP" are the direct and indirect portrops of BVIII DVIII CP" are the direct and indirect portrops of BVIII DVIII CP" are the direct portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct portrops of BVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct portrops of BVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct portrops of BVIII DVIII CP" and MPM BioVentures III-LC ("BVIII LC") are the direct portrops of BVII
- (1) GmbH & Co. Beteiligungs KG ("BVIII KG"); 342 by MPM BioVentures III Parallel Fund, L.P. ("BVIII LLC"); and 219 MPM Asset Management Investors 2003 BVIII LLC ("BVIII LLC") are the direct and indirect partners of BVIII, BVIII QP, BVIII PF and BVIII KG.
- (2) The shares are held as follows: 101,302 by BVIII; 1,506,678 by BVIII QP; 127,334 by BVIII KG; 45,504 by BVIII PF; and 29,180 by BVAM LLC. The Reporting Person is a member of BVIII LLC and BVAM LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- (3) The shares were sold as follows: 302 by BVIII; 4,495 by BVIII QP; 380 by BVIII KG; 136 by BVIII PF; and 87 BVAM LLC. BVIII GP and BVIII LLC are the direct and indirect partners of BVIII, BVIII QP, BVIII PF and BVIII KG.
- (4) The shares are held as follows: 101,000 BVIII; 1,502,183 by BVIII QP; 126,954 by BVIII KG; 45,368 by BVIII PF; and 29,093 by BVAM LLC. The Reporting Person is a member of BVIII LLC and BVAM LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.